Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

Leukemia

Volumn 29, Issue 1, 2015, Pages 11-19

  Gjertsen, B T ^a,b   Schoffski P ^c  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

VOLASERTIB; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER PATIENT; CANCER THERAPY; DRUG RESPONSE; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOLID TUMOR; ANTAGONISTS AND INHIBITORS; NEOPLASMS;

HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PTERIDINES;

EID: 84920698054     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.222     Document Type: Review

References (75)

1. Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004; 5: 429-440.
2. Medema RH, Lin CC, Yang JC. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res 2011; 17: 6459-6466.
3. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100: 5789-5794.
4. Tamura Y, Simizu S, Muroi M, Takagi S, Kawatani M, Watanabe N et al. Polo-like kinase 1 phosphorylates and regulates Bcl-x(L) during pironetin-induced apoptosis. Oncogene 2009; 28: 107-116.
5. Rizki A, Mott JD, Bissell MJ. Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res 2007; 67: 11106-11110.
6. Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994; 91: 1736-1740.
7. Renner AG, Dos SC, Recher C, Bailly C, Créancier L, Kruczynski A et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009; 114: 659-662.
8. Tsykunova G, Reikvam H, Ahmed AB, Nepstad I, Gjertsen BT, Bruserud O. Targeting of polo-like kinases and their cross talk with Aurora kinases-possible therapeutic strategies in human acute myeloid leukemia? Expert Opin Investig Drugs 2012; 21: 587-603.
9. Weiss L, Efferth T. Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol 2012; 1: 38.
10. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010; 9: 643-660.
11. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 316-322.
12. Schöffski P, Blay JY, De GJ, Brain E, Machiels JP, Soria JC et al. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 2010; 46: 2206-2215.
13. Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010; 5: 1060-1067.
14. Chu Q, Gandhi L, Stephenson J, Johnson BE, Govindan R, Bradford D et al. An open-label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer. J Thorac Oncol 2009; 4(Part2): 200.
15. Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM et al. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma of the pancreas-a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. Br J Cancer 2012; 107: 280-286.
16. Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P et al. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol 2013; 163: 214-222.
17. Hofheinz RD, Al-Batran SE, Hochhaus A, Jäger E, Reichardt VL, Fritsch H et al. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 2010; 16: 4666-4674.
18. Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S et al. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocel-lular carcinoma due to low intratumoral drug levels. Neoplasia 2012; 14: 410-419.
19. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009; 15: 3094-3102.
20. Paller CJ, Wissing MD, Rosmus NS, Hammers H, Rudin CM, Carducci MA et al. Preclinical synergy of Plk1 inhibitors and HDACIs. Cancer Res 2011; 71: 2557.
21. Wissing MD, Rosmus N, Gonzalez M, Hammers H, Carducci MA, Kachhap SK. Targeting prostate cancer through a combination of Polo-like kinase inhibitors and histone deacetylase inhibitors. Cancer Res 2010; 70: 5414.
22. Lin CC, Lin Y-M, Tsai Y-C, Pu Y-S, Cheng A-L, Yang JC. Combined cytotoxic effects of volasertib and cisplatin in urothelial carcinoma cells. Cancer Res 2012; 72: 3725.
23. Smith M, Keir S, Maris J, Kolb A, Reynolds P, Kang M et al. Pediatric Preclinical Testing Program (PPTP) evaluation of volasertib (BI 6727), a Polo-like kinase (PLK) inhibitor. Cancer Res 2012; 72: LB-317.
24. Lanvers-Kaminsky C, Abbou S, Daudigeos-Dubus E, Molenaar J, Verschuur A, Caron H et al. Anti-tumor activity of the PLK inhibitor volasertib (BI 6727) and the aurora kinase inhibitor BI 811283 in pediatric malignancies. Eur J Cancer 2012; 48: 78.
25. Jayanthan A, Cooper T, Dunn SE, Lewis VA, Narendran A. Cooperative lethality of Polo-like kinases (PLK) and Aurora kinases (AK) in refractory pediatric leukemia. Blood 2012; 120: 3573.
26. Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012; 48: 179-186.
27. Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 2014; 10: 305-312.
28. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485: 260-263.
29. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
30. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromo-domains. Cancer Res 2013; 73: 3336-3346.
31. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011; 478: 529-533.
32. Kettenbach AN, Schweppe DK, Faherty BK, Pechenick D, Pletnev AA, Gerber SA. Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells. Sci Signal 2011; 4: rs5.
33. Cholewa BD, Desotelle JA, Ahmad N. Small molecule inhibitor of Polo-like kinase 1 (Plk1) causes significant melanoma growth delay and regression in vivo. Cancer Res 2012; 72: 1920.
34. Krause M, Kummer B, Deparade A, Eicheler W, Pfitzmann D, Yaromina A et al. Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation. Radiother Oncol 2013; 108: 422-428.
35. Lin CC, Su WC, Yen C, Cheng A, Lu Y, Hsu C et al. A phase I dose-escalation study of the polo-like kinase 1 inhibitor volasertib (BI 6727) with two different dosing schedules in patients with advanced solid malignancies. J Clin Oncol 2011; 29: 3046.
36. Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP et al. An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 2014; 120: 976-982.
37. Pujade-Lauraine E, Weber BE, Ray-Coquard I, Vergote I, Selle F, Del Campo JM et al. Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC). J Clin Oncol 2013; 31: 5504.
38. Ellis PM, Leighl N, Hirsh V, Reaume MN, Blais N, Wierzbicki R et al. A randomised, open-label phase II trial of volasertib as monotherapy and in combination with standard dose pemetrexed compared with pemetrexed monotherapy in second-line non-small cell lung cancer (NSCLC). J Thorac Oncol 2013; 8: 2307.
39. Deleporte A, Dumez H, Awada A, Costermans J, Meeus M, Berghmans T et al. Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors. J Clin Oncol 2011; 29: 3031.
40. Dumez H, Gombos A, Schöffski P, Gil T, Vulsteke C, Meeus M-A et al. Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors. J Clin Oncol 2012; 30: 3018.
41. Peeters M, Machiels JP, Pilz K, De Smet M, Strelkowa N, Liu D et al. Phase I study of volasertib (BI 6727) combined with afatinib (BIBW 2992) in advanced solid tumors. J Clin Oncol 2013; 31: 2521.
42. De Braud FG, Cascinu S, Spitaleri G, Pilz K, Clementi L, Liu D et al. A phase I dose escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors. J Clin Oncol 2013; 31: 2556.
43. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 2. Available at: URL http://www.nccn. org (last accessed 10 October 2013).
44. Fey MF, Dreyling M. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v158-v161.
45. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
46. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet 2013; 381: 484-495.
47. Estey E. AML in older patients: are we making progress? Best Pract Res Clin Haematol 2009; 22: 529-536.
48. Kantarjian H, O'Brien S. Questions regarding frontline therapy of acute myeloid leukemia. Cancer 2010; 116: 4896-4901.
49. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
50. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 1114-1124.
51. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-2677.
52. Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int J Hematol 2012; 96: 186-193.
53. Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009; 23: 1564-1576.
54. Bug G, Schlenk RF, Müller-Tidow C, Lübbert M, Krämer A, Fleischer F et al. Phase I/II study of BI 6727 (volasertib), an intravenous polo-like kinase-1 (Plk1) inhibitor, in patients with acute myeloid leukemia (AML): results of the dose finding for BI 6727 in combination with low-dose cytarabine. Blood 2010; 116: abstract 3316.
55. Bug G, Müller-Tidow C, Schlenk RF, Krämer A, Lübbert M, Krug U et al. Phase I/II study of volasertib (BI 6727), an intravenous polo-like kinase (Plk) inhibitor, in patients with acute myeloid leukemia (AML): updated results of the dose finding phase I part for volasertib in combination with low-dose cytarabine (LD-Ara-C) and as monotherapy in relapsed/refractory AML. Blood 2011; 118: abstract 1549.
56. Döhner H, Bug G, Müller-Tidow C, Krämer A, Lübbert M, Krug U et al. Phase I/II study of volasertib, an intravenous Polo-like kinase inhibitor (Plk), in patients with relapsed/refractory acute myeloid leukemia (AML): updated phase I results for volasertib monotherapy. Haematologica 2014; 99: abstract S649.
57. Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM et al. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood 2014; e-pub ahead of print 8 July 2014; doi: http://dx.doi.org/10.1182/blood-2014-03-560557.
58. Chen YJ, Lin YP, Chow LP, Lee TC. Proteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide-induced mitotically arrested cells. Proteomics 2011; 11: 4331-4345.
59. Renner AG, Creancier L, Dos Santos C, Fialin C, Recher C, Bailly C et al. A functional link between polo-like kinase 1 and the mammalian target-of-rapamycin pathway? Cell Cycle 2010; 9: 1690-1696.
60. Younes A, Samad N. Utility of mTOR inhibition in hematologic malignancies. Oncologist 2011; 16: 730-741.
61. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 2010; 95: 819-828.
62. Récher C, Dos Santos C, Demur C, Payrastre B. mTOR: a new therapeutic target in acute myeloid leukemia. Cell Cycle 2005; 4: 1540-1549.
63. Oppermann FS, Grundner-Culemann K, Kumar C, Gruss OJ, Jallepalli PV, Daub H. Combination of chemical genetics and phosphoproteomics for kinase signaling analysis enables confident identification of cellular downstream targets. Mol Cell Proteomics 2012; 11: O111.012351.
64. Schaab C, Oppermann F, Pfeifer H, Klammer M, Tebbe A, Oellerich T et al. Global phosphoproteome analysis of AML bone marrow reveals predictive markers for the treatment with AC220. Blood 2012; 120: 786.
65. Hjelle SM, Forthun RB, Haaland I, Reikvam H, Sjoholt G, Bruserud O et al. Clinical proteomics of myeloid leukemia. Genome Med 2010; 2: 41.
66. Skavland J, Jorgensen KM, Hadziavdic K, Hovland R, Jonassen I, Bruserud O et al. Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer J 2011; 1: e4.
67. Anensen N, Hjelle SM, Van BW, Haaland I, Silden E, Bourdon JC et al. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene 2012; 31: 1533-1545.
68. Lee M, Daniels MJ, Venkitaraman AR. Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression. Oncogene 2004; 23: 865-872.
69. Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M et al. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther 2010; 9: 2079-2089.
70. Sanhaji M, Kreis NN, Zimmer B, Berg T, Louwen F, Yuan J. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors. Cell Cycle 2012; 11: 543-553.
71. Dawson MA, Gudgin EJ, Horton SJ, Giotopoulos G, Meduri E, Robson S et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 2014; 28: 311-320.
72. Stewart HJ, Horne GA, Bastow S, Chevassut TJ. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Med 2013; 2: 826-835.
73. Tie F, Banerjee R, Conrad PA, Scacheri PC, Harte PJ. Histone demethylase UTX and chromatin remodeler BRM bind directly to CBP and modulate acetylation of histone H3 lysine 27. Mol Cell Biol 2012; 32: 2323-2334.
74. Forthun RB, Sengupta T, Skjeldam HK, Lindvall JM, McCormack E, Gjertsen BT et al. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS One 2012; 7: e48992.
75. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990; 9: 253-266.